In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

The dulaglutide data were revealed today at the annual American Diabetes Association meeting. Dulaglutide could restore some pride in Lilly's much-maligned R&D engine.

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

对于 2 型糖尿病（T2D）血糖控制不佳的患者，提升 Dulaglutide（胰高血糖素样肽 - 1 受体激动剂，GLP - 1）剂量不如换用 Tirzepatide。研究发现，换用并加量 Tirzepatide 者 40 周后 21% 的人糖化血红蛋白 A1c（HbA1c）达标，且减重效果更好，安全性相似。此研究为 T2D 治疗提供新方向。

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to ...

Full results of REWIND show dulaglutide significantly reduces CV events in patients with type 2 diabetes who primarily have CVD risk factors, rather than CVD itself. The major effect seems to be ...

Eli Lilly & Co's experimental once-weekly diabetes drug dulaglutide proved superior in late-stage clinical trials to three other widely used medicines that are dosed more frequently, the company ...